Business
Innoviva to Participate in the Cantor Global Healthcare Conference
BURLINGAME, Calif.--(BUSINESS WIRE)-- Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and other
About this update from Innoviva, Inc.
[{"type":"text","content":" BURLINGAME, Calif.--(BUSINESS WIRE)--\nInnoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will participate in a fireside chat at the Cantor Global Healthcare Conference in New York, NY on Wednesday, September 27, 2023 at 1:50 p.m. Eastern Time.\n\n\nA live webcast of the fireside chat can be accessed under “Events & Presentations” in the Investor Relations section of the Company’s website at https://investor.inva.com/presentations-events. The webcast will be available for replay for 90 days following the event.\n\n\nAbout Innoviva\n\n\nInnoviva, Inc., is a diversified holding company with a portfolio of royalties and other healthcare assets, including Innoviva Specialty Therapeutics, a subsidiary focused on delivering innovative therapies in critical care and infectious disease. Innoviva’s royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA® (fluticasone furoate/vilanterol, FF/VI) and ANORO® ELLIPTA® (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. ANORO®, RELVAR® and BREO® are trademarks of the GSK group of companies. For more information on Innoviva, please visit here.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20230919112391/en/\n\nInvestors & Media:\nArgot Partners\n(212) 600-1902\[email protected]\n\n\nSource: Innoviva, Inc.","length":3489,"tagName":"div"}]